Gyre Therapeutics, Inc.
GYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001124105
No open-market purchases or sales by Gyre Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $57.1M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Gyre Therapeutics, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 32 | 16 | −16 |
| Shares | 2.15M | 606.8K | −1.55M (−71.8%) |
| Value | $1.04M | $15.6M | +$14.6M (+1,404.6%) |
New holders (3)
Institutions that held Gyre Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citigroup Inc | 7,748 | $199.0K | 0.00% |
| Wetzel Investment Advisors, Inc. | 266 | $7.00K | 0.00% |
| Advisory Services Network, LLC | 66 | $1.70K | 0.00% |
Sold out (19)
Institutions that held Gyre Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Morgan Stanley | 97,745 | $47.1K |
| Kynam Capital Management, LP | 90,058 | $43.4K |
| Nantahala Capital Management, LLC | 67,800 | $32.7K |
| Johnson & Johnson | 66,951 | $32.3K |
| Acadian Asset Management LLC | 63,793 | $30.0K |
| Barclays PLC | 60,204 | $29.0K |
| Citadel Advisors LLC | 47,966 | $23.1K |
| Group One Trading, L.P. | 46,778 | $22.6K |
| Susquehanna International Group, LLP | 42,347 | $20.4K |
| Colorado Capital Management, Inc. | 34,165 | $16.0K |
| HSBC Holdings PLC | 32,528 | $15.7K |
| Bank of America Corp | 22,484 | $10.8K |
| Two Sigma Securities, LLC | 20,039 | $9.66K |
| Raymond James & Associates | 12,900 | $6.22K |
| Arete Wealth Advisors, LLC | 10,845 | $5.23K |
| Cutler Group LP | 5,500 | $2.00K |
| BNP Paribas Arbitrage, SA | 277 | $134 |
| Royal Bank of Canada | 253 | $0 |
| GWM Advisors LLC | 1 | $0 |